Feed BCYC
BC

Bicycle Therapeutics plc

BCYC · NASDAQ

$3.65 -1.08% (-$0.04)
1M -13.21%
Market Cap $255.4M
P/E Ratio -
Div. Yield -
ROE 33.22%

Bulios Fair Price

$4.3

17.8% upside

Trenutna cena

$3.65

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BCYC trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
72 /100
Cheap
P/S 4.17x
P/B 0.50x
P/E N/A
Growth
100 /100
Growing
Rev. growth 71.21%
Book val. growth 31.09%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 100.00%
Net margin 311.11%
FCF margin 335.91%
Quality
1 /100
Poor
ROIC 37.98%
ROE 33.22%
Asset turnover 0.10x
Debt
69 /100
Low
Debt/Equity 0.03x
Current ratio 12.08x
Int. coverage -976.62x
Stability
26 /100
Unstable
Beta 1.54x
Rev. volatility 38.96%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BCYC
Online

O podjetju

Bicycle Therapeutics (BCYC) is a biotechnology company based in the United Kingdom that focuses on developing novel therapeutics based on bicycle peptide technology. This technology enables the creation of small, stable, and highly specific therapeutics with the potential to treat various diseases, including cancer and immune-related disorders. Bicycle Therapeutics is dedicated to developing drugs based on its bicycle peptide platform and building partnership agreements with pharmaceutical companies.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Kevin Lee

Employees

288

Headquarters

Cambridge

Prihajajoči dogodki

29 OKT.

Earnings

Upcoming earnings report

40d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.